



Jeune Aesthetics to Present Pre-clinical Data Highlighting the Potential of KB303 in Elastin Production at the ASDS 2021 Virtual Meeting

November 19, 2021

- *Pre-clinical program evaluated proper formation and deposition of elastic fibers into the skin extracellular matrix in mice*
- *KB303 holds potential to be the first-ever directed approach to increase production of elastin in the skin*

PITTSBURGH, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc., a wholly-owned subsidiary of [Krystal Biotech, Inc.](#), (“Krystal”) (NASDAQ: KRY5) today announced the presentation of preclinical data supporting the ongoing development of KB303, an innovative, investigational gene-delivery therapy designed to enable local, full-length elastin production in the skin. The data will be presented at the American Society for Dermatologic Surgery (ASDS) 2021 Virtual Meeting to be held November 19-21, 2021.

“The field of aesthetic medicine has been looking for a therapeutic approach that could increase the deposition of full-length elastic fibers in skin for decades,” said Dr. Bhushan Hardas, President of Jeune Aesthetics. “Using our proprietary gene delivery platform, we’ve engineered KB303 to deliver the *ELN* gene and help cells naturally replenish elastin that has been lost due to photo-damage and aging. We’re excited to present these first-ever data on KB303 that, while early, show promise in the potential to be the first approach to produce elastin to naturally improve skin elasticity.”

Abstract information:

Title: KB303, An Innovative And Minimally Invasive HSV-1-Based Therapy to Improve Skin Elasticity

Presentation Information: The video oral abstract will be available on-demand anytime throughout the meeting to attendees starting November 19 at 8:30 a.m. CT

Cutaneous aging affects many layers of the skin, leading to wrinkling, atrophy of the dermis, and loss of elasticity associated with damage to the underlying elastin, a key extracellular matrix protein which provides resilience and elasticity to tissues and organs. Elastic fibers are key components of the skin’s extracellular matrix, consisting of the protein elastin and microfibrillar proteins that assemble into long strands. Due to their low turnover rate, elastin fibers are particularly prone to the accumulation of damage, resulting in a loss of skin resilience and elasticity with age.

About KB303

KB303 leverages the Skin TARgeted Delivery (STAR-D) platform and is designed to stimulate biorejuvenation of the skin via delivery of the gene that encodes for elastin protein when it is administered by intradermal injection.

About Jeune Aesthetics, Inc.

Jeune Aesthetics, Inc., a subsidiary of Krystal Biotech, is a biotechnology company leveraging a clinically validated gene-delivery platform to fundamentally address – and reverse – the biology of aging and/or damaged skin. For more information, please visit <http://www.jeuneinc.com>.

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ:KRY5) is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases. For more information, please visit <http://www.krystalbio.com>, and follow @KrystalBiotech on [LinkedIn](#) and [Twitter](#).

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., or its wholly-owned subsidiary, JeuneAesthetics, Inc., including but not limited to statements about the development of Jenue’s product candidates, such as plans for the design, conduct and timelines of ongoing clinical trials of KB301, the clinical utility of KB301, the ability of KB301 to fundamentally address and potentially reverse the biology of aging or damaged skin, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or trials will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of product candidates including KB301 and such other important factors as are set forth under the caption “Risk Factors” in Krystal’s annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystal’s and Jeune’s views as of the date of this release. Krystal anticipates that subsequent events and developments will cause its views to change. However, while Krystal may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Krystal’s views as of any date subsequent to the date of this release.

CONTACTS:

Investor Contact:

Whitney Ijem
Krystal Biotech
wijem@krystalbio.com

Media:

Lauren Barbiero

Real Chemistry

lbarbiero@realchemistry.com

Source: Krystal Biotech, Inc.; Jeune Aesthetics, Inc.